Approximately 30% of patients with epilepsy have inadequate seizure control despite taking antiepileptic drugs (AEDs).^[@R1]^ Surgery with removal of the anterior and mesial temporal lobe (TL) structures may result in favorable seizure outcome in 60% to 75% of patients, but long-term seizure freedom is achieved in only 50% with most of those patients still taking medication.^[@R2]^ Biomarkers predicting outcome of epilepsy surgery would be of high clinical interest.

According to the transporter hypothesis of drug resistance, regional overactivity of multidrug efflux transporters, such as P-glycoprotein (Pgp), impedes access of substrate AEDs to their brain target sites, thereby rendering them ineffective.^[@R3]^ The hypothesis is well supported in some animal models of epilepsy.^[@R4],[@R5]^ However, relevant in vivo human data are sparse. PET with the radiolabeled Pgp substrate (*R*)-\[^11^C\]verapamil (VPM) can be used to noninvasively measure cerebral Pgp function.^[@R6]^ Two previous studies in patients with drug-resistant TL epilepsy (TLE) showed a trend for increased Pgp function in the ipsilateral TL compared with the contralateral side,^[@R7]^ and a significant bilateral increase in TL Pgp function compared with seizure-free patients.^[@R8]^ It remains unclear whether Pgp overactivity is static or changes with disease progression, and to what extent it depends on seizure activity or AED load.^[@R9]^

In the present study, we examined patients with TLE using VPM-PET before and after TL surgery in order to (1) assess whether postoperative changes in seizure frequency and AED load are associated with changes in Pgp function, and (2) correlate in vivo measurements of Pgp function with ex vivo immunohistochemistry. We hypothesized that optimal outcome after surgery would be associated with a reduction in Pgp activity.

METHODS {#s1}
=======

Standard protocol approvals, registrations, and patient consents. {#s1-1}
-----------------------------------------------------------------

The study was approved by the Ethics Committee of the Medical University of Vienna and was conducted as a pilot study. Written informed consent was obtained from all patients.

Patients. {#s1-2}
---------

Seven patients (2 females; median age at time of first PET scan: 50 years, range 33--54) with drug-resistant TLE^[@R10]^ were included in this study after surgical treatment with either selective amygdalohippocampectomy (n = 4) or anteromedial temporal lobectomy (n = 3). Patients were recruited from a group of 9 patients studied preoperatively with VPM-PET^[@R7]^; 2 previous patients were not included because one patient was not available for follow-up after surgery and the other had no arterial input function for presurgery PET. A second VPM-PET scan was performed a median of 42 months (range 17--54) after surgery (see [table](#T1){ref-type="table"} for details). Surgery outcome in individual patients was ranked according to (1) complete seizure freedom after surgery, (2) type and number of seizures during follow-up period after surgery, and (3) intake of AEDs (figure e-1 on the *Neurology*® Web site at [Neurology.org](http://www.neurology.org/)).

###### 

Clinical, EEG, and MRI data for patients with drug-resistant TLE who underwent surgery^a^
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PET and MRI. {#s1-3}
------------

Dynamic VPM-PET scans were acquired on an Advance PET scanner (GE Medical Systems, Waukesha, WI) as described before,^[@R7]^ with arterial blood sampled throughout. Radiolabeled metabolites of VPM were measured in discrete arterial blood samples using a previously described solid-phase extraction assay.^[@R7]^ For all patients, T1-weighted MRIs were acquired before and after surgery with an Achieva 3.0T scanner (Philips Medical Systems, Best, the Netherlands). The PET and MRIs were processed as described previously.^[@R7]^ PET data analysis was performed using the Hammersmith 3-dimensional maximum probability atlas.^[@R7]^ Six TL volumes of interest (VOIs) (amygdala, parahippocampal gyrus, anterior temporal lobe, middle and inferior temporal gyrus, superior temporal gyrus, and posterior temporal lobe) and 2 extratemporal VOIs (superior parietal gyrus and cerebellum) were chosen for analysis. The hippocampus itself could not be analyzed because of spillover of radioactivity from the adjacent choroid plexus, which showed high VPM uptake.

Kinetic modeling of PET data was performed by using an arterial input function corrected for polar radiolabeled metabolites of VPM and a 1-tissue 2--rate constant compartment model to derive the transfer rate constant *K*~1~ (mL/min/cm^3^) of VPM from plasma into brain as an outcome parameter of Pgp function, with low *K*~1~ indicating high Pgp function.^[@R7]^ To minimize the influence of radiolabeled metabolites of VPM on *K*~1~ estimates, only the first 10 minutes of the PET data were considered for kinetic modeling.^[@R8]^

Immunohistochemistry. {#s1-4}
---------------------

Brain tissue (hippocampus for all patients, and anterior-mesial parts of the TL of 3 patients) was removed during epilepsy surgery and fixed in 10% neutral buffered formalin immediately after surgery. For immunohistochemical staining, brain sections were prepared and probed with antibodies recognizing Pgp (clones, JSB1 1:400, C219 1:80, C494 1:1,000; Alexis Biochemicals, Lausen, Switzerland) followed by quantitative image assessment as published.^[@R8],[@R11]^

Statistical analyses. {#s1-5}
---------------------

Statistical testing was performed using Prism 5.0 software (GraphPad Software, La Jolla, CA). Data are presented as mean ± SD for PET data and median (range) for demographic data. Friedman test with Dunn post hoc test was used when multiple groups were compared, and Wilcoxon matched-pairs signed rank test was used when 2 groups were compared. Correlations were assessed by calculating Spearman rank correlation coefficients (*r*~*s*~). A value of *p* \< 0.05 was considered statistically significant.

RESULTS {#s2}
=======

Preoperative Pgp activity. {#s2-1}
--------------------------

In all patients, VPM-*K*~1~ values from preoperative VPM-PET scans were lower in regions pathophysiologically connected to the epileptic focus (amygdala: 0.032 ± 0.011; superior temporal gyrus: 0.037 ± 0.012) compared with a reference region considered not to be involved in epileptogenic pathways (cerebellum: 0.045 ± 0.012) ([figure 1A](#F1){ref-type="fig"}). Moreover, VPM-*K*~1~ was lower in amygdala than in posterior TL (0.043 ± 0.011). There were no differences between TL VPM-*K*~1~ values ipsilaterally or contralaterally to the seizure focus.

![Pre- and postoperative Pgp activity and correlation with Pgp expression\
(A) VPM-*K*~1~ values in different brain regions located ipsilateral to the seizure focus of individual patients before epilepsy surgery (\*\*\* *p* \< 0.001, \*\* *p* \< 0.01; Friedman test with Dunn post hoc test). (B) Pgp immunopositive labeling in the surgically resected hippocampus of 2 patients. (C) Correlation of percentage area of Pgp immunopositive labeling in the surgically resected hippocampus with VPM-*K*~1~ values in ipsilateral anterior TL (*r*~*s*~ = Spearman rank correlation coefficient). (D) VPM-*K*~1~ values in different brain regions located ipsilateral to the seizure focus of individual patients after epilepsy surgery. Brain regions affected by surgery are not shown (\* *p* \< 0.05; Friedman test with Dunn post hoc test). amyg = amygdala; ant-TL = anterior temporal lobe; MITG = middle and inferior temporal gyrus; p = patient; para-HC = parahippocampal gyrus; Pgp = P-glycoprotein; post-TL = posterior temporal lobe; SPG = superior parietal gyrus; STG = superior temporal gyrus; TL = temporal lobe; VPM = (*R*)-\[^11^C\]verapamil.](NEUROLOGY2013567750FF1){#F1}

Correlation of preoperative Pgp activity with Pgp expression. {#s2-2}
-------------------------------------------------------------

Pgp immunoreactivity in surgically resected hippocampal specimens was determined using Pgp-specific antibodies ([figure 1B](#F1){ref-type="fig"}). The higher the Pgp immunoreactivity in surgically resected hippocampal specimens, the lower were the ipsilateral VPM-*K*~1~ values for anterior TL (*r*~*s*~ = −0.821, *p* = 0.034; [figure 1C](#F1){ref-type="fig"}) and superior temporal gyrus (*r*~*s*~ = −0.857, *p* = 0.024).

Postoperative Pgp activity. {#s2-3}
---------------------------

Postoperative VPM-*K*~1~ values were lower in superior temporal gyrus (0.033 ± 0.007) compared with cerebellum (0.041 ± 0.008) and the posterior TL (0.041 ± 0.009; [figure 1D](#F1){ref-type="fig"}). The AED load was reduced in all patients, with 2 patients coming off all AEDs, but this did not affect peripheral metabolism of VPM; i.e., fractions of polar radiolabeled metabolites of VPM in plasma at 10 minutes after injection were similar before (0.140 ± 0.039) and after surgery (0.136 ± 0.042, *p* = 0.938).

Correlation of pre- and postoperative Pgp activity with postoperative outcome. {#s2-4}
------------------------------------------------------------------------------

Patients with better outcome had lower mean presurgical VPM-*K*~1~ values in ipsilateral TL (higher Pgp function) than patients with poorer outcome (*r*~*s*~ = 0.837, *p* = 0.024) ([figure 2A](#F2){ref-type="fig"}). Patients with better outcome had high areas of Pgp immunopositive labeling in surgically resected hippocampal specimens, while patients with poorer outcome had low Pgp immunoreactivity (*r*~*s*~ = −0.782, *p* = 0.048; [figure 2B](#F2){ref-type="fig"}). In the 3 patients with best postoperative outcome (patients 1 and 6: seizure-free and without medication; patient 3: seizure-free and with very low AED load), VPM-*K*~1~ values increased relative to preoperative PET scans in all brain VOIs studied, whereas *K*~1~ values decreased in patients with worst outcome ([figure 2C](#F2){ref-type="fig"}).

![Correlation of Pgp activity and Pgp expression with postoperative outcome\
(A) Correlation of mean presurgical VPM-*K*~1~ values in ipsilateral TL with surgery outcome rank in individual patients (see the methods section and figure e-1 for definition of surgery outcome rank order; *r*~*s*~ = Spearman rank correlation coefficient). (B) Correlation of percentage area of Pgp immunopositive labeling in the surgically resected hippocampus with surgery outcome rank in individual patients. (C) Mean percent change in VPM-*K*~1~ values across all studied TL regions located ipsilateral to the seizure focus in postsurgery PET scan relative to presurgery PET scan. Patients 3 and 4 were both assigned rank 3, but the antiepileptic drug load of patient 3 was lower than that of patient 4. p = patient; Pgp = P-glycoprotein; TL = temporal lobe; VPM = (*R*)-\[^11^C\]verapamil.](NEUROLOGY2013567750FF2){#F2}

DISCUSSION {#s3}
==========

In a longitudinal pilot VPM-PET study in patients with drug-resistant TLE before and after TL surgery with a median follow-up period after surgery of 6 years (range 4--7), we detected a "normalization" of Pgp activity in patients with long-lasting seizure freedom postoperatively. Our preoperative in vivo PET findings are supported by direct correlation with Pgp immunoreactivity in surgical specimens in the same patients. Furthermore, high Pgp activity in epileptogenic pathways preoperatively was associated with better postoperative outcome. Our longitudinal PET data suggest that Pgp overactivity is dynamic rather than static, and seizure freedom and reduction in AED load are associated with reversal of upregulation.

In line with the transporter hypothesis of drug resistance, we found significantly lower VPM-*K*~1~ values in some TL brain regions close to the presumed epileptic focus (amygdala, superior temporal gyrus) as compared with a reference region outside the TL (cerebellum) or with a region more distant from the focus (posterior TL), pointing to Pgp overactivity in epileptogenic brain tissue. Consistent with previous findings, we show that Pgp overactivity was not restricted to the ipsilateral TL, but also extended to the contralateral side involved in epileptogenic pathways.^[@R8]^

After epilepsy surgery, patients with optimal surgery outcome defined as seizure freedom and withdrawal of AEDs had global VPM-*K*~1~ increases relative to presurgery PET scans, suggestive of decreased Pgp function. This "return to normal" after successful epilepsy surgery is consistent with our recent report of higher VPM-*K*~1~ values in pharmacosensitive compared with drug-refractory patients^[@R8]^ and with findings in postmortem brain tissue, which showed almost no Pgp overexpression in the sclerotic hippocampus of patients with epilepsy who had entered terminal remission before death.^[@R11]^

A previous immunohistochemistry study showed higher Pgp expression in the TL white matter of patients with postoperative seizure relapse compared with postoperatively seizure-free patients,^[@R12]^ in keeping with our finding of increased Pgp activity postoperatively in patients with poorer outcome. Our preoperative in vivo PET data and ex vivo immunohistochemistry, however, suggest that Pgp overactivity in epileptogenic pathways and hippocampal overexpression are associated with optimal outcome after TL surgery. This discrepancy in predicting postoperative outcome might be explained by methodologic differences: we quantified hippocampal Pgp immunoreactivity, whereas Kwan et al.^[@R12]^ used semiquantitative approaches and found differences in Pgp immunoreactivity in TL white matter, but also a trend toward higher neuronal Pgp expression in postoperatively seizure-free patients. The latter finding is in keeping with our in vivo PET finding of Pgp overactivity in TL gray matter as a predictor of optimal outcome.

Our pilot study was not designed to assess the predictive ability of VPM-PET as biomarker of surgery outcome; this should be tested prospectively in a larger cohort, and integrated with other known risk factors for less favorable outcome, such as psychiatric comorbidities and incompleteness of resection. Moreover, our study cannot distinguish between the effects of seizure cessation from dose decrease or discontinuation of AEDs on postoperative Pgp function. Our cohort was too small to statistically compare subgroups of patients, e.g., seizure-free (n = 4) vs not seizure-free (n = 3) patients, or seizure-free patients without AEDs (n = 2) vs seizure-free patients on AEDs (n = 2), with meaningful results. Alternatively, one could conduct a prospective study to leave the patients on their medication for the first year after surgery and to acquire 2 separate postsurgery PET scans, before and after the change in medication. However, our data suggest that AED exposure also affects Pgp activity, because our outcome ranking mainly based on seizure burden after surgery correlates with AED load. Another limitation of this study is that we were not able to obtain VPM-*K*~1~ values in hippocampus, which would require the availability of a PET scanner with higher spatial resolution and advanced image reconstruction to overcome the spillover from the high VPM uptake in the adjacent choroid plexus.^[@R8]^

Our study cannot address whether Pgp overactivity is the cause of drug resistance in TLE, and thus "surgical" removal of this overactivity contributed to seizure freedom, or whether upregulation is a marker of seizure burden rather than a cause.^[@R9]^ In both scenarios, Pgp overactivity may reduce target concentrations of AEDs and thereby possibly contribute to drug resistance. Our study demonstrates that Pgp overactivity is not static, and thus could be therapeutically targeted by drugs that inhibit or downregulate Pgp to possibly prevent development of, or bring about reversal of, drug resistance mediated by Pgp.

Our data confirm previous findings that VPM-PET reflects Pgp function in vivo in patients with TLE, and that cerebral Pgp overactivity is associated with drug resistance in TLE.^[@R8]^ Our postoperative VPM-PET data extend previous findings, indicating a "normalization" of Pgp function in those patients who benefited most from surgery. Our findings also suggest that Pgp overactivity in the TL on preoperative VPM-PET might be indicative of optimal postoperative outcome.

Supplementary Material
======================

###### Data Supplement

Supplemental data at [Neurology.org](http://neurology.org/)
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